{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:00:12Z","timestamp":1792184412198,"version":"4.4.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.2967\/jnumed.123.265952","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T11:40:43Z","timestamp":1686224443000},"page":"1417-1423","source":"Crossref","is-referenced-by-count":44,"title":["SNMMI Consensus Statement on Patient Selection and Appropriate Use of\n                    <sup>177<\/sup>\n                    Lu-PSMA-617 Radionuclide Therapy"],"prefix":"10.2967","volume":"64","author":[{"given":"Thomas A.","family":"Hope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip J.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023091409501492000_64.9.1417.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2023091409501492000_64.9.1417.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"2023091409501492000_64.9.1417.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4008"},{"key":"2023091409501492000_64.9.1417.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"2023091409501492000_64.9.1417.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"2023091409501492000_64.9.1417.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206"},{"key":"2023091409501492000_64.9.1417.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt194"},{"key":"2023091409501492000_64.9.1417.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2023091409501492000_64.9.1417.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"2023091409501492000_64.9.1417.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"2023091409501492000_64.9.1417.11","doi-asserted-by":"crossref","unstructured":"Clarke NW Armstrong AJ Thiery-Vuillemin A . Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:10.1056\/EVIDoa2200043.","DOI":"10.1056\/EVIDoa2200043"},{"key":"2023091409501492000_64.9.1417.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2023091409501492000_64.9.1417.13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"2023091409501492000_64.9.1417.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023091409501492000_64.9.1417.15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023091409501492000_64.9.1417.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2023091409501492000_64.9.1417.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261982"},{"key":"2023091409501492000_64.9.1417.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263638"},{"key":"2023091409501492000_64.9.1417.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"2023091409501492000_64.9.1417.20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2022.40.6_suppl.010","article-title":"PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603) [abstract]","volume":"40","author":"Buteau","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023091409501492000_64.9.1417.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263262"},{"key":"2023091409501492000_64.9.1417.22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","article-title":"Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution","volume":"19","author":"Ferreira","year":"2019","journal-title":"Cancer Imaging."},{"key":"2023091409501492000_64.9.1417.23","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy [abstract]","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023091409501492000_64.9.1417.24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2023091409501492000_64.9.1417.25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy\u2013like picture","volume":"83","author":"Sch\u00e4fer","year":"2023","journal-title":"Eur Urol."},{"key":"2023091409501492000_64.9.1417.26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","article-title":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study","volume":"78","author":"Gafita","year":"2020","journal-title":"Eur Urol."},{"key":"2023091409501492000_64.9.1417.27","doi-asserted-by":"crossref","first-page":"55567","DOI":"10.18632\/oncotarget.15698","article-title":"Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget."},{"key":"2023091409501492000_64.9.1417.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264456"},{"key":"2023091409501492000_64.9.1417.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023091409501492000_64.9.1417.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T12:53:57Z","timestamp":1694696037000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.2967\/jnumed.123.265952"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265952","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}